Fast Locator 2011-2012: Celsis Analytical Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Celsis Analytical Services



Celsis Analytical Services specializes in methods validation and testing for industry offering a wide range of services in analytical chemistry and microbiological testing for compendial, non-compendial, and client-specific needs, plus stability testing and storage programs. And we're up-to-date on ICH and the latest changes to the USP as well as the Ph EUR and JP.

Analytical Chemistry:
Our chemistry department can perform more than 90% of the testing requirements defined in the United States Pharmacopeia (USP) and its counterparts around the globe. We continuously invest in the latest instrumentation, including multiple HPLC, GC, IC and LC-MS/MS plus dissolution and AA. Count on us for your full monograph testing, with confidence.

Biological Sciences:
Our microbiology scientists combine decades of microbiological testing experience in facilities that are equipped with the latest instrumentation and equipment including two Class 100 clean rooms, DiversiLab strain typing System, Vitek 60® Microbial Identification Systems, Celsis Rapid Detection systems and particle size analyzers.

Stability Testing and Storage:
Since the establishment of pharmaceutical expiration dating provisions, we have led the way in supplying the appropriate testing and storage conditions to meet regulatory and customer demands for product and package stability. From photostability to Zone IV conditions, we can handle your stability testing and storage needs.


Regions covered:

Global: Asia, North America, Europe, Latin America.


Outsourcing services provided:

Analytical Services

  • Chemistry and stability
  • Bioanalytical testing
  • Biosafety and product characterization
  • Microbiology
  • Particle characterization

Website:

www.celsis.com/labs

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here